ES2567779T3 - Composición farmacéutica o nutracéutica - Google Patents

Composición farmacéutica o nutracéutica Download PDF

Info

Publication number
ES2567779T3
ES2567779T3 ES10174148.6T ES10174148T ES2567779T3 ES 2567779 T3 ES2567779 T3 ES 2567779T3 ES 10174148 T ES10174148 T ES 10174148T ES 2567779 T3 ES2567779 T3 ES 2567779T3
Authority
ES
Spain
Prior art keywords
reps
press
alkalized
tribulus
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10174148.6T
Other languages
English (en)
Inventor
Jeffrey M. Golini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43334398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2567779(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2567779T3 publication Critical patent/ES2567779T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

Una composición farmacéutica o nutracéutica que comprende una sustancia orgánica alcalinizada seleccionada entre el grupo que comprende concentrado de proteína de suero; aminoácidos; y mezclas de los mismos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
Animal Peso en gramos % de Aumento 03/14/5 664,80 03/17/5 665,80 03/21/5 669,80 03/24/5 670,80 12,02 % Total
imagen10
Animal Peso en gramos % de Aumento Ensayo 5 335,89 Peso Inicial
01/06/5 342,80
01/10/5 338,80
01/13/5 374,30
01/17/5 380,20
01/20/5 387,80
01/24/5 418,80
01/27/5 418,80
01/31/5 430,20
02/03/5 433,30
02/07/5 439,20
02/10/5 444,30
02/14/5 459,30
02/17/5 467,30
02/21/5 475,80
02/24/5 486,30
02/28/5 492,80
03/05/5 494,30
03/09/5 509,30
03/14/5 509,80
03/17/5 509,80
03/21/5 513,00
03/24/5 515,00 53,32 % Total
Animal Peso en gramos % de Aumento Ensayo 6 307,80 Peso Inicial
01/06/5 320,34
01110/5 323,80
01/13/5 350,00
01/17/5 357,80
01/20/5 370,80
01/24/5 395,80
01/27/5 404,00
01/31/5 410,60
02/03/5 412,20
02/07/5 413,40
02/10/5 429,80
02/14/5 429,80
02/17/5 429,90
02/24/5 434,30
02/28/5 441,80
03/05/5 441,80
03/09/5 470,80
11
imagen11
imagen12
imagen13
imagen14
La evaluación de los efectos antiproliferativos de los compuestos sometidos a ensayo frente a la línea de células HD-MY-Z derivada de linfoma de Hodgkin reveló que ejercían una fuerte actividad inhibitoria, de nuevo superior para los aceites alcalinizados. A una concentración de 1 mg/ml, las células viables eran 30,7 después de exposición a grasas convencionales y 26,8 después de tratamiento con aceites alcalinizados. La superioridad de los aceites
5 alcalinizados en términos de potencia se corrobora con los valores de CI50 calculados -0,27 mg/ml para las grasas convencionales con respecto a 0,22 mg/ml para las procesadas.
Los resultados para las tres líneas de células derivadas del mieloma múltiple también demostraron la superioridad de los aceites alcalinizados con respecto a los no estabilizados.
10 Los datos presentados indican que a través del panel de células malignas, los aceites alcalinizados demostraban que ejercían efectos antiproliferativos superiores con respecto a los no tamponados, tal como se pone en evidencia mediante la comparación de punto a punto de fracciones de supervivencia después del tratamiento con concentraciones equivalentes así como mediante yuxtaposición de los valores de CI50 calculados. En la técnica se
15 observa bien que la potencia antiproliferativa de un compuesto dado in vitro está gobernada por su estabilidad en las condiciones experimentales. Por lo tanto, considerando las condiciones controladas equivalentes del experimento, la mayor actividad observada de los aceites alcalinizados se podría atribuir únicamente a la estabilidad superior proporcionada por las manipulaciones del procesamiento.
20 Referencias:
1. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 1983. 65 (1-2): p. 55-63.
25 2. Konstantinov, S.M., H. Eibl, y M.R. Berger, BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. Br J Haematol, 1999. 107 (2): p. 365-80.
Tabla 1: Efectos antiproliferativos de grasas no procesadas con respecto a aceites alcalinizados en un panel líneas de células tumorales humanas, tal como se evalúa mediante el ensayo de reducción de MTT-colorante después de 30 una exposición continua de 72 h.
Línea celular
Origen CI50 (mg/ml)
Grasas no procesadas
Grasas tamponadas
HL-60
Leucemia promielocítica aguda 0,41 ± 0,07 0,32 ± 0,03
LAMA-84
Leucemia mieloide crónica 0,18 ± 0,04 0,12 ± 0,02
HD-MY-Z
Linfoma de Hodgkin 0,27 ± 0,04 0,22 ± 0,03
OPM-2
Mieloma múltiple 0,12 ± 0,02 0,08 ± 0,01
U-266
Mieloma múltiple 0,32 ± 0,05 0,24 ± 0,06
RPMI
Mieloma múltiple 0,20 ± 0,03 0,17 ± 0,01
Ejemplo 8: Estudio que administra un extracto de Tribulus terrestris con respecto a extracto de Tribulis terrestris ácido
35 Extracto de Tribulus Terrestris 500 mg
Bicarbonato sódico 10 mg Bicarbonato potásico 10 mg
40 Finalidad del Estudio: Observar si la hierba de Tribulus alcalinizada supera a la hierba de Tribulus ácida.
Procedimientos: Durante 30 días se administraron al sujeto 500 mg de Tribulus ácida a primera hora de la A.M. en un estómago vacío, tomada en forma de cápsulas. A continuación, se cambia al sujeto a 500 mg de Tribulus alcalinizada tomada a primera hora de la A.M. en un estómago vacío. El sujeto del ensayo era un hombre adulto con
45 experiencia en el deporte del culturismo.
Los niveles de resistencia se observaron al comienzo del estudio basándose en los siguientes levantamientos:
Press de pecho en banco inclinado 50 Press de piernas
16
Press de hombros Pull downs El equipo de ensayo se localizaba en el local del Oz Fitness Center. El ensayo se realizó una vez a la semana. No
sin cambio en el programa de dieta o ejercicio.
Resultados:
Antes del Ensayo
Press de pecho en banco inclinado
84 Kg x 10 reps
Press de piernas
184 Kg x 10 reps
Press de hombros
41 Kg x 10 reps
Pull downs
68 Kg x 10 reps
Semana 1 con Tribulus ácida:
Press de pecho en banco inclinado
84 Kg x 10 reps
Press de piernas
184 Kg x 10 reps
Press de hombros
41 Kg x 10 reps
Pull downs
68 Kg x 10 reps
Semana 2 con Tribulus ácida:
Press de pecho en banco inclinado
141 Kg x 10 reps
Press de piernas
193 Kg x 10 reps
Press de hombros
43 Kg x 10 reps
Pull downs
73 Kg x 10 reps
Semana 3 con Tribulus ácida:
Press de pecho en banco inclinado
141 Kg x 10 reps
Press de piernas
193 Kg x 10 reps
Press de hombros
43 Kg x 10 reps
Pull downs
73 Kg x 10 reps
Semana 4 con Tribulus ácida:
Press de pecho en banco inclinado
143 Kg x 10 reps
Press de piernas
197 Kg x 10 reps
Press de hombros
43 Kg x 10 reps
Pull downs
77 Kg x 10 reps
Semana 1 con Tribulus alcalinizada:
Press de pecho en banco inclinado
102 Kg x 10 reps
Press de piernas
206 Kg x 10 reps
Press de hombros
45 Kg x 10 reps
Pull downs
77 Kg x 10 reps
Semana 2 con Tribulus alcalinizada:
Press de pecho en banco inclinado
111 Kg x 10 reps
Press de piernas
443 Kg x 10 reps
Press de hombros
48 Kg x 10 reps
Pull downs
141 Kg x 10 reps
Semana 3 con Tribulus alcalinizada:
Press de pecho en banco inclinado
125 Kg x 10 reps
17
imagen15
imagen16

Claims (1)

  1. imagen1
ES10174148.6T 2009-08-26 2010-08-26 Composición farmacéutica o nutracéutica Active ES2567779T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27519009P 2009-08-26 2009-08-26
US275190P 2009-08-26

Publications (1)

Publication Number Publication Date
ES2567779T3 true ES2567779T3 (es) 2016-04-26

Family

ID=43334398

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10174148.6T Active ES2567779T3 (es) 2009-08-26 2010-08-26 Composición farmacéutica o nutracéutica

Country Status (4)

Country Link
US (5) US20110052729A1 (es)
EP (2) EP2298090B1 (es)
ES (1) ES2567779T3 (es)
PL (1) PL2298090T3 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162797A (en) 2010-12-29 2017-07-14 Abbott Lab Nutritional products including a novel fat system including monoglycerides
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
NZ711956A (en) 2013-03-08 2018-06-29 Axiom Foods Inc Rice protein supplements
CN110868870A (zh) 2017-05-12 2020-03-06 艾斯姆食品公司 大米产物及制备它们的系统和方法
JPWO2022039215A1 (es) * 2020-08-21 2022-02-24

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2357069A (en) * 1941-04-07 1944-08-29 Victor Chemical Works Iron fortification of flour
GB820995A (en) 1957-05-10 1959-09-30 Unilever Ltd Improvements in or relating to fat compositions
US3392195A (en) * 1963-09-09 1968-07-09 Galat Alexander Amino acid derivatives
US4267197A (en) 1978-06-21 1981-05-12 Pacific Kenyon Corporation Animal feed supplement as a thixotropic stable suspension
US4411917A (en) 1981-11-23 1983-10-25 Nutrisearch Company Fabricated shellfish products containing whey protein concentrate composition and method of preparation
JPS58134963A (ja) 1982-02-03 1983-08-11 Masuda Teruo 大豆食品の製造法
US4994284A (en) * 1986-06-27 1991-02-19 Union Oil Company Of California Animal feed supplement suspension
DK179687D0 (da) 1987-04-08 1987-04-08 Farma Food As Praeparat
US5024849A (en) 1990-05-01 1991-06-18 Nestec S.A. Liquid coffee whitener
US5629023A (en) * 1991-12-31 1997-05-13 Bland; Jeffrey S. Medical food composition for metabolic detoxification
DE4320853C2 (de) 1993-06-23 1996-06-27 Kbi Kunststoffbeutel Produktio Feste Mineralstoffmischung
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
JP3213666B2 (ja) * 1994-02-28 2001-10-02 治彦 末岡 クレアチン飲料の製造方法
DE19514568A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl-pyridazinone
US5973005A (en) * 1998-02-26 1999-10-26 Bio-Bontanica, Inc. Aqueous creatine solution and process of producing a stable, bioavailable aqueous creatine solution
US6294579B1 (en) 1999-10-11 2001-09-25 Joseph W. Carnazzo Method for improving delivery of tyrosine supplementation
US20030235629A1 (en) * 1999-11-06 2003-12-25 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
US6399661B1 (en) * 2000-06-26 2002-06-04 Jeffrey M. Golini Oral creatine supplement and method for making same
US20070142325A1 (en) 2001-01-08 2007-06-21 Gustavsson Nils O Starch
US6451361B1 (en) * 2001-05-29 2002-09-17 Agri-Nutrients Technology Group, Inc. Alkali metal magnesium phosphate hydrate buffering feed mineral
AU2002314802A1 (en) 2001-05-31 2002-12-09 Abbott Laboratories Polymer controlled induced viscosity fiber system and uses thereof
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
GB0323240D0 (en) 2003-10-03 2003-11-05 Golini Jeffrey M Creatine composition and use
US7582326B2 (en) 2003-10-29 2009-09-01 Kraft Foods Global Brands Llc Method of deflavoring whey protein using membrane electrodialysis
EP1752152A4 (en) 2004-05-31 2011-02-16 Senju Pharma Co MEANS FOR VISUALIZING TRANSPARENT WEAVE
ATE504332T1 (de) 2004-09-01 2011-04-15 Chitra Vasant Savangikar Verbindungen, zusammensetzungen, formulierungen und herstellungsverfahren dafür, behandlungsverfahren, handhabung von übersäuerung und verwandte erkrankungen
US8445536B2 (en) 2005-03-31 2013-05-21 Ajinomoto Co., Inc. Arginine-containing compositions and methods for increasing blood flow using same
US20070202058A1 (en) * 2006-02-27 2007-08-30 Calwood Nutritionals, Inc. Compositions for treating gastric reflux
ATE524073T1 (de) 2006-03-27 2011-09-15 Nestec Sa Molkenprotein micellen
KR100839794B1 (ko) * 2007-02-08 2008-06-19 농업회사법인 주식회사 자연에 알칼리 곡물의 제조방법
US8263164B2 (en) 2007-07-18 2012-09-11 Campina Nederland Holding B.V. Heat stable nutritional beverage and method of preparing it
WO2009113845A1 (en) 2008-03-12 2009-09-17 N.V. Nutricia High protein liquid enteral nutritional composition
AU2009214706A1 (en) * 2008-02-12 2009-08-20 Mars Incorporated Meat analog product
NL2001788C2 (nl) 2008-07-11 2010-01-12 Stichting Energie Werkwijze voor de decompositie van N2O, katalysator daarvoor en bereiding van deze katalysator.
US20090005320A1 (en) * 2008-09-02 2009-01-01 Bruce Kneller Compositions comprising amino acid bicarbonate and methods of use thereof

Also Published As

Publication number Publication date
US20150164937A1 (en) 2015-06-18
EP2298090B1 (en) 2016-01-13
US20220288126A1 (en) 2022-09-15
US11376282B2 (en) 2022-07-05
PL2298090T3 (pl) 2016-07-29
US20160220610A1 (en) 2016-08-04
US20190083541A1 (en) 2019-03-21
US20200405766A1 (en) 2020-12-31
EP2298090A1 (en) 2011-03-23
EP3001912A1 (en) 2016-04-06
US20110052729A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
ES2567779T3 (es) Composición farmacéutica o nutracéutica
CO2022009085A2 (es) Derivados espiránicos sustituidos de cadena lineal
ECSP13012418A (es) Derivados de ácido 2-quinolin-acético como compuestos antivirales para vih
SV2011003830A (es) Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico
UY35465A (es) Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
GT200600297A (es) Nuevos anticuerpos anti-madcam
UY34048A (es) Proteínas de repetición enlazantes de il4/il13 y sus usos
UY29244A1 (es) Combinaciones medicas
CL2011001692A1 (es) Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros.
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
PH12019502241A1 (en) Berberine alkaloids in the prevention and/or treatments of intestinal disease
ECSP23095641A (es) Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
ES2656913T3 (es) Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes
ES2817623T3 (es) Aditivo de complemento alimenticio
Rathi et al. A case report of acute lymphoblastic leukemia–An Ayurvedic approach
Saghafi et al. Comparison of efficacy and side effects of propolis with chemotherapy and chemotherapy alone for neoadjuant therapy of ovarian cancer
Takeda et al. The feasibility and preliminary effectiveness of an exercise program in patients with depression
JP2016514143A5 (es)
MD1375Y (ro) Metodă de tratament al afecţiunilor inflamatorii ale ţesuturilor moi şi articulaţiilor
AR082005A1 (es) Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino
Ozcay Various toxicities: 4 case reports
IN2014DE00123A (es)
Cerchione Haematologic toxicity: case report
TH158883B (th) องค์ประกอบสำหรับใช้ในการป้องกันหรือการรักษาโรคลำไส้อักเสบชนิดเนื้อตาย ในทารกและเด็กเล็ก
Hussain Ausama Ayoob Yacob